As previously described in T-ALL, PI3K signaling-altered patients had a poorer response to chemotherapy (Supplementary Table 1), a shorter overall survival compared to wild-type cases (Fig. 1B and Supplementary Fig. 1B), and higher incidences of disease relapse (Supplementary Fig. 1C). This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.